These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34924820)

  • 1. Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.
    Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Bhat SA
    Pathol Oncol Res; 2021; 27():1609826. PubMed ID: 34924820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of ARID1A negative expression in gastric cancer.
    Ashizawa M; Saito M; Min AKT; Ujiie D; Saito K; Sato T; Kikuchi T; Okayama H; Fujita S; Endo H; Sakamoto W; Momma T; Ohki S; Goto A; Kono K
    Sci Rep; 2019 May; 9(1):6769. PubMed ID: 31043675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
    Wang X; Che K; Shi T; Liu Q; Xu X; Wu H; Yu L; Liu B; Wei J
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1583-1595. PubMed ID: 35294647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
    Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
    PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation.
    Kase K; Saito M; Nakajima S; Takayanagi D; Saito K; Yamada L; Ashizawa M; Nakano H; Hanayama H; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Shiraishi K; Kohno T; Kono K
    Carcinogenesis; 2021 Feb; 42(1):21-30. PubMed ID: 33196828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy.
    Loe AKH; Francis R; Seo J; Du L; Wang Y; Kim JE; Hakim SW; Kim JE; He HH; Guo H; Kim TH
    J Exp Med; 2021 Jun; 218(6):. PubMed ID: 33822841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique characteristics of
    Kim YS; Jeong H; Choi JW; Oh HE; Lee JH
    Saudi J Gastroenterol; 2017; 23(5):268-274. PubMed ID: 28937020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells.
    Tong G; Cheng B; Li J; Wu X; Nong Q; He L; Li X; Li L; Wang S
    Cancer Med; 2019 Nov; 8(16):7044-7054. PubMed ID: 31557409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of ARID1A mutations with mRNA levels and protein expression in gastric carcinoma.
    Hwang I; Cho Y; Kang SY; Kim DG; Ahn S; Lee J; Kim KM
    Pathol Res Pract; 2024 Mar; 255():155063. PubMed ID: 38324965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
    Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
    Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
    Han N; Kim MA; Lee HS; Kim WH
    Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
    Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
    PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AT-rich Interaction Domain 1A Gene Variations: Genetic Associations and Susceptibility to Gastric Cancer Risk.
    Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Din I; Bashir H
    Pathol Oncol Res; 2020 Oct; 26(4):2237-2246. PubMed ID: 32377988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveiling the immunoregulatory role of interferon-induced transmembrane protein 2 through the JAK/STAT3/PDL1 pathway in gastric cancer.
    Liu Y; Liang J; Huang J; Li X; Huang J; Wang J
    Int Immunopharmacol; 2024 Dec; 142(Pt B):113221. PubMed ID: 39321709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
    Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
    Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.
    Zhang X; Sun Q; Shan M; Niu M; Liu T; Xia B; Liang X; Wei W; Sun S; Zhang Y; Liu XS; Song Q; Yang Y; Ma Y; Liu Y; Yang L; Ren Y; Zhang G; Pang D
    PLoS One; 2013; 8(1):e53931. PubMed ID: 23349767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
    Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
    Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-34a suppresses the proliferation and invasion of gastric cancer by modulating PDL1 in the immune microenvironment.
    Yong H; Fu J; Gao G; Shi H; Zheng D; Zhou X
    Mol Cell Probes; 2020 Oct; 53():101601. PubMed ID: 32445780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CRISPR/Cas9-Engineered
    Lo YH; Kolahi KS; Du Y; Chang CY; Krokhotin A; Nair A; Sobba WD; Karlsson K; Jones SJ; Longacre TA; Mah AT; Tercan B; Sockell A; Xu H; Seoane JA; Chen J; Shmulevich I; Weissman JS; Curtis C; Califano A; Fu H; Crabtree GR; Kuo CJ
    Cancer Discov; 2021 Jun; 11(6):1562-1581. PubMed ID: 33451982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
    Gu Y; Zhang P; Wang J; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
    Cancer Immunol Immunother; 2023 May; 72(5):1199-1208. PubMed ID: 36369379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.